会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • 3β-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof
    • 3β-氨基偶氮二异辛烷杂芳族衍生物的制备方法及其治疗用途
    • US07456192B2
    • 2008-11-25
    • US10494639
    • 2002-10-30
    • Thierry ImbertBarbara MonseWouter Koek
    • Thierry ImbertBarbara MonseWouter Koek
    • A61K31/4353A61K31/4365A61K31/46C07D471/04C07D419/04
    • C07D491/04C07D495/04
    • The invention concerns compounds of general formula 1, wherein: A, B, D and E represent one or two nitrogen atoms, the others being carbon atoms; X represents a S or, a O, thereby forming a bicyclic fused heteroaromatic, such as thieno[2,3-b]pyridine, furo[2,3-b]pyridine, thieno[3,2-b]pyridine, furo[3,2-b]pyridine, thieno[2,3-b]pyrazine, furo[2,3-b]pyrazine, thieno[2,3-c]pyridine, furo[2,3-c]pyridine, thieno[3,2-c]pyridine and furo[3,2-c]pyridine; R1 represents a linear or branched C1-C6 alkoxy group, a linear or branched C1-C6 alkylthio group; R2 represents a linear, branched, cyclic C2-C8 group, a 2- or 3-thienylmethyl group, or a benzyl group optionally substituted by one or several halogens, F, Cl, Br, I, C1-C4alkyl, C1-C4 alkoxy, CF3, CN, NO2, OH; and their pharmaceutically acceptable salts. Said compounds are anti-dopaminergic agents.
    • 本发明涉及通式1的化合物,其中:A,B,D和E代表一个或两个氮原子,其余是碳原子; X表示S或O,由此形成双环稠合杂芳族化合物,例如噻吩并[2,3-b]吡啶,呋喃并[2,3-b]吡啶,噻吩并[3,2-b]吡啶,呋喃并[ 3,2-b]吡啶,噻吩并[2,3-b]吡嗪,呋喃并[2,3-b]吡嗪,噻吩并[2,3-c]吡啶,呋喃并[2,3-c]吡啶,噻吩并[ 3,2-c]吡啶和呋喃并[3,2-c]吡啶; R 1表示直链或支链C 1 -C 6烷氧基,直链或支链C 1 -C 6烷氧基,直链或支链C 1 -C 6 - 烷硫基 R 2表示直链,支链,环状C 2 -C 8亚烷基,2-或3-噻吩基甲基或任选被一个或多个卤素取代的苄基, F,Cl,Br,I,C 1 -C 4烷基,C 1 -C 4烷氧基, CF 3,CN,NO 2,OH; 及其药学上可接受的盐。 所述化合物是抗多巴胺能药。
    • 7. 发明授权
    • 3-oxo-2(H)-1,2,4-triazine derivatives as ligands of 5 HT1A receptors
    • 3-羟基-2(H)-1,2,4-三嗪衍生物作为5个HT1A受体的配体
    • US06303603B1
    • 2001-10-16
    • US09529728
    • 2000-04-14
    • Jean-Francois PatoiseauElisabeth Dupont-PasselaigueWouter Koek
    • Jean-Francois PatoiseauElisabeth Dupont-PasselaigueWouter Koek
    • A61K3153
    • C07D253/075C07D401/12C07D403/12C07D405/12C07D471/04
    • The invention concerns novel 3-oxo-(2H)-1,2,4-triazine derivatives of general formula (I) in which R1 represents: hydrogen, when A is an optionally substituted nitrogen atom; a linear or branched 1-C4 alkyl group; a C1-C4phenyl alkyl group, the phenyl ring being optionally substituted by one or several groups such as C1-C4 alkyl, C1-C3 alkoxy, halogen, trifluoromethyl. R2 represents: hydrogen; a linear or branched C1-C4 alkyl radical; a C1-C4 phenyl or phenylalkyl group, the phenyl ring being optionally substituted by one or several groups such as C1-C4 alkyl, C1-C3 alkoxy, halogen, trifluoromethyl. A represents an oxygen atom or a nitrogen atom optionally NR3 substituted. R3 represents hydrogen or a methyl group. B represents a group such as (IIa) in which Ar itself represents an aromatic structure such as phenyl, pyridyl or pyrimidyl, optionally substituted by one or several groups such as C1-C3 alkyl, C1-C3 alkoxy, hydroxy, trifluoromethyl or halogen and n can be whole numbers ranging between 3 and 5; (IIb) in which Ar is as defined in formula (IIa) and m can be a whole number ranging between 1 and 2; (IIc) in which R4 represents hydrogen or a C1-C3 alkyl group and n can be whole numbers ranging between 3 and 5.
    • 本发明涉及通式(I)的新的3-氧代 - (2H)-1,2,4-三嗪衍生物,其中当R1是任意取代的氮原子时,R 1表示:氢; 直链或支链的1-C4烷基; C1-C4苯基烷基,苯环任选被一个或多个基团取代,例如C 1 -C 4烷基,C 1 -C 3烷氧基,卤素,三氟甲基。 R2表示:氢; 直链或支链C 1 -C 4烷基; C 1 -C 4苯基或苯基烷基,苯环任选被一个或几个基团例如C 1 -C 4烷基,C 1 -C 3烷氧基,卤素,三氟甲基取代。 A表示氧原子或任选被NR 3取代的氮原子。 R3表示氢或甲基。 B表示其中Ar本身表示芳族结构的基团,例如苯基,吡啶基或嘧啶基,任选被一个或多个基团例如C 1 -C 3烷基,C 1 -C 3烷氧基,羟基,三氟甲基或卤素取代, n可以是3到5之间的整数; (IIb)其中Ar如式(IIa)中所定义,m可以是1和2之间的整数; (IIc)其中R4表示氢或C1-C3烷基,n可以是3至5的整数。
    • 8. 发明授权
    • Cyclohexane derivatives difunctionalised in 1,4 as ligands of 5T H1A receptors
    • 环己烷衍生物在1,4中作为5T H1A受体的配体双功能化
    • US06191130B1
    • 2001-02-20
    • US09529783
    • 2000-04-14
    • Jean-François PatoiseauElisabeth Dupont-PasselaigueWouter Koek
    • Jean-François PatoiseauElisabeth Dupont-PasselaigueWouter Koek
    • C07D25306
    • C07D253/075C07D403/12C07D405/12
    • The invention concerns novel cyclohexane derivatives difunctionalised in 1.4 of general formula (1) in which A represents a group such as (IIa) in which Ar itself represents an aromatic structure such as phenyl or pyrimidinyl optionally substituted by one or several groups such as C1-C3 alkyl, C1-C3 alkoxy, trifluoromethyl or halogen (IIb); B represents a heterocyclic group such as: 3,5-dioxo-(2H,4H)-1,2,4 triazine substituted in position 2 (IIIa); 3-oxo-(2H)-1,2,4 triazine substituted in position 5 (IIIb); 3,5-dioxo-6-amino-(2H,4H)-1,2,4-triazine (IIIc) in which R represents a C1-C3 alkyl group. The invention also concerns the salts of compounds of general formula I with pharmaceutically acceptable acids. It also concerns the various “cis” and “trans” isomers and the various enantiomers with asymmetric carbons.
    • 本发明涉及在1.4通式(1)中双官能化的新型环己烷衍生物,其中A代表其中Ar本身表示芳族结构的基团,例如苯基或嘧啶基,其任选被一个或多个基团取代,如C1- C3烷基,C1-C3烷氧基,三氟甲基或卤素(IIb); B表示杂环基,例如:位置2(IIIa)取代的3,5-二氧代 - (2H,4H)-1,2,4-三嗪; 在位置5(IIIb)取代的3-氧代 - (2H)-1,2,4-三嗪; 3,5-二氧代-6-氨基 - (2H,4H)-1,2,4-三嗪(IIIc),其中R表示C1-C3烷基。 本发明还涉及通式I的化合物与药学上可接受的酸的盐。 它还涉及各种“顺式”和“反式”异构体和具有不对称碳的各种对映异构体。